Article Text

PDF
P285 Assessing The Impact Of Varenicline Initiation During Acute Hospital Admission For Current Smokers With Respiratory Diseases: 18-month Experience From An Inner City District Teaching Hospital
  1. A Ainley,
  2. E Pang,
  3. B Coleman,
  4. M Stern,
  5. LJ Restrick
  1. Department of Respiratory Medicine, Whittington Health NHS Trust, London, UK

Abstract

Introduction Smoking is a significant cause of respiratory disease and risk factor for chronic obstructive pulmonary disease (COPD) and asthma admissions. 70% of smokers admitted to hospital want to quit and quit smoking interventions during acute admission are NICE recommended.1 Many patients with respiratory disease are highly nicotine-dependent and varenicline is an effective treatment1,2 but is not routinely initiated during admission.

Method We retrospectively reviewed the notes of all patients prescribed varenicline during in-patient stay on the respiratory ward over 18 months (August 2012–January 2014). Baseline data included demographics, disease details (diagnosis, spirometry) and smoking history (tobacco/cannabis use, pack/joint-years). The primary outcomes were carbon monoxide (CO) validated quit rates at 4-weeks and self-reported quit rates at 6-months and 1-year.

All patients were seen on the ward by a smoking cessation advisor and after discharge as per NICE guidance.1 Nicotine withdrawal during varenicline initiation was treated with standard combination nicotine replacement therapy.1

Results 44 patients (17M:27F) were prescribed varenicline during admission. Mean (range) age was 61 (23–81) years with median (range) 50 (8–180) pack-years. 8/44 (18%) also smoked cannabis. 29 (66%) had COPD, 7 (16%) asthma, and 8 (18%) had both. Mean (SD) FEV1 was 1.18 (0.52)L (n = 40) with FEV1%predicted 47 (21)% (n = 26). 7 patients (16%) died; all from smoking-related diseases, within 18 months of admission with mean (range) age at death 71 (61–78) years. 2 were lost to follow-up. CO-validated 4-week quit rate was 48% (21/44). Self-reported 6-month and 1-year quit rates were 41% (18/44) and 20% (9/44) respectively. Only 4/44 (9%) stopped varenicline early due to side-effects (nausea/headache).

Conclusion Varenicline was safe and well-tolerated when initiated in hospital. The 4-week 48% quit rate for these ‘sick’ smokers was almost as high as the 52% national target for ‘well’ smokers. Self-reported 6-month quit rates were almost as good as the best published rates with intensive support in COPD (41% cf 49%).2 Varenicline should be used as a treatment for smokers admitted with respiratory disease.1

References

  1. NICE PH guidance 48. Smoking cessation in secondary care. 2013

  2. Jiménez Ruiz et al. Nicotine and Tobacco Research. 2012;14(9):1035-1039

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.